Allogeneic marrow transplantation for acute non-lymphoblastic leukemia in relapse using fractionated total body irradiation

Leuk Res. 1982;6(3):389-94. doi: 10.1016/0145-2126(82)90102-3.


Twenty-three patients with acute non-lymphoblastic leukemia in relapse were treated with cyclophosphamide, fractionated total body irradiation (200 rad/day for six days) and allogeneic marrow transplantation. Six patients are alive in remission 756-1306 days following transplantation. One patient died of infection on day 17 without evidence of engraftment; all others achieved sustained engraftment. Eight patients died of recurrent leukemia, four of interstitial pneumonitis, two of infection, one of veno-occlusive disease of the liver and one of cardiac failure. The median survival time was 181 days.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Graft vs Host Reaction
  • Humans
  • Leukemia / radiotherapy
  • Leukemia / therapy*
  • Middle Aged
  • Probability
  • Prognosis
  • Recurrence
  • Whole-Body Irradiation